#1 Clinical Trials Search in Europe

N-Methyl-2-(4′-Methylaminophenyl)-6-Hydroxybenzothiazole

This article discusses the use of N-Methyl-2-(4′-Methylaminophenyl)-6-Hydroxybenzothiazole, also known as PiB or Pittsburgh compound B, in clinical trials for early-onset Alzheimer’s disease caused by genetic mutations. The drug is being studied as part of a larger trial investigating potential disease-modifying therapies for dominantly inherited Alzheimer’s disease (DIAD). The research aims to assess the safety, tolerability, and effectiveness of PiB in slowing cognitive decline and improving disease-related biomarkers in individuals at risk for or affected by DIAD.

Table of Contents

What is PiB?

PiB, short for Pittsburgh compound B, is a medical substance with the scientific name N-METHYL-2-(4′-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE. It’s also known by other names such as 6-OH-BTA-1 and 2-[4-(Methylamino)phenyl]-1,3-benzothiazol-6-ol.[1] This compound is not a treatment for Alzheimer’s disease, but rather a powerful tool used in research to help understand and diagnose the condition.

Use in Alzheimer’s Research

PiB is primarily used in a type of brain imaging called PET (Positron Emission Tomography) scanning. In Alzheimer’s research, PiB-PET scans are used to visualize and measure the amount of amyloid plaques in the brain. Amyloid plaques are abnormal clusters of protein fragments that build up between nerve cells and are a hallmark of Alzheimer’s disease.[1]

By using PiB in PET scans, researchers can:

  • Detect the presence of amyloid plaques in the brain
  • Monitor changes in amyloid levels over time
  • Assess the effectiveness of potential Alzheimer’s treatments in reducing amyloid buildup

Clinical Trial Information

PiB is being used in a significant clinical trial for Alzheimer’s disease. This trial, known as the “Dominantly Inherited Alzheimer Network Trial” (DIAN-TU), is studying potential treatments for a rare form of Alzheimer’s disease called Dominantly Inherited Alzheimer Disease (DIAD).[1]

Key points about this trial include:

  • It’s a Phase II/III trial, which means it’s testing both the effectiveness and safety of potential treatments
  • The trial is focusing on people who have a genetic mutation that causes early-onset Alzheimer’s disease
  • Participants include both those who already have symptoms and those who are at risk but don’t yet have symptoms
  • The study uses PiB-PET scans as one of its primary ways to measure the effectiveness of treatments

How PiB is Administered

In the clinical trial, PiB is administered as an injection. Specifically, it’s given through an intravenous bolus, which means it’s injected directly into a vein in a single, rapid dose.[1] This allows the PiB to quickly circulate through the body and reach the brain, where it can bind to amyloid plaques for imaging.

Safety and Dosage

The safety of PiB is carefully monitored in clinical trials. Here are some important points about its use:[1]

  • The maximum daily dose is 18 millicuries (mCi). A millicurie is a unit used to measure radioactivity.
  • The maximum total dose over the course of the study is 90 mCi.
  • The treatment period can last up to 208 weeks (about 4 years).

It’s important to note that PiB is used in very small amounts for imaging purposes and is not a treatment itself. The radiation exposure from PiB-PET scans is carefully controlled and monitored to ensure participant safety.

Importance in Dominantly Inherited Alzheimer’s Disease

PiB plays a crucial role in studying Dominantly Inherited Alzheimer’s Disease (DIAD). This rare form of Alzheimer’s is caused by specific genetic mutations and often leads to early-onset dementia, sometimes affecting people in their 30s or 40s.[1]

By using PiB-PET scans, researchers can:

  • Detect amyloid buildup in the brain before symptoms appear
  • Track how quickly amyloid accumulates over time
  • Assess whether potential treatments can slow down or stop amyloid buildup
  • Compare amyloid levels between those who carry the genetic mutation and those who don’t

This information is invaluable for understanding how Alzheimer’s disease progresses and for developing and testing new treatments that could potentially prevent or slow down the disease.

Aspect Details
Drug Name N-Methyl-2-(4′-Methylaminophenyl)-6-Hydroxybenzothiazole (PiB)
Trial Phase Phase II/III
Condition Studied Dominantly Inherited Alzheimer’s Disease (DIAD)
Main Objective Assess safety, tolerability, and efficacy in slowing cognitive decline and improving biomarkers
Administration Intravenous injection, max 18 mCi daily, 90 mCi total
Study Duration Up to 208 weeks
Key Measurements Cognitive function, clinical assessments, brain imaging, biomarkers in CSF and blood
Eligibility Individuals with or at risk for DIAD-causing mutations, within specific age ranges

FAQ

  • What is N-Methyl-2-(4'-Methylaminophenyl)-6-Hydroxybenzothiazole (PiB)? N-Methyl-2-(4'-Methylaminophenyl)-6-Hydroxybenzothiazole, also known as PiB or Pittsburgh compound B, is a chemical compound being studied in clinical trials for early-onset Alzheimer's disease. It is used as an imaging agent to help detect and measure amyloid plaques in the brain, which are associated with Alzheimer's disease.
  • What is the main objective of the clinical trial using PiB? The main objective of the clinical trial is to assess the safety, tolerability, and effectiveness of PiB and other investigational products in participants with Alzheimer's disease-causing mutations. The study aims to determine if treatment with the study drug can slow the progression of cognitive impairment or improve disease-related biomarkers.
  • Who is eligible to participate in this clinical trial? The trial includes two main groups: a secondary prevention population (individuals within 10 years before or after their estimated age of symptom onset) and a primary prevention population (individuals 11 to 25 years younger than their estimated age of symptom onset). Participants must have a known eligible mutation or be at 50% risk due to an affected parent or sibling.
  • How is PiB administered in the clinical trial? PiB is administered as an intravenous injection. The maximum daily dose is 18 millicuries (mCi), with a maximum total dose of 90 mCi over the course of the study, which can last up to 208 weeks.
  • What are some of the outcomes being measured in this clinical trial? The trial measures various outcomes, including changes in cognitive function, clinical assessments, brain imaging (such as amyloid PET scans using PiB), and biomarkers in cerebrospinal fluid and blood. These measurements help researchers evaluate the effectiveness of the treatment and its impact on the progression of Alzheimer's disease.

Ongoing Clinical Trials on N-Methyl-2-(4′-Methylaminophenyl)-6-Hydroxybenzothiazole

  • Study of Remternetug for Prevention of Disease Progression in People at Risk for or With Early Onset Inherited Alzheimer’s Disease

    Not yet recruiting

    4 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Spain

  • Study on Lecanemab and Drug Combination for Patients with Early Onset Alzheimer’s Disease Due to Genetic Mutation

    Not recruiting

    4 1
    Investigated diseases:
    Investigated drugs:
    Germany Ireland Italy The Netherlands Spain

Glossary

  • Dominantly Inherited Alzheimer's Disease (DIAD): A rare form of Alzheimer's disease caused by specific genetic mutations that are inherited from a parent. It typically leads to early-onset Alzheimer's, with symptoms appearing before age 65.
  • Biomarker: A measurable indicator of a biological state or condition. In Alzheimer's research, biomarkers can include proteins in blood or cerebrospinal fluid, or brain imaging results that indicate the presence or progression of the disease.
  • Amyloid: A protein that can build up in the brain, forming plaques that are characteristic of Alzheimer's disease. PiB is used to detect and measure these amyloid plaques.
  • PET (Positron Emission Tomography): An imaging technique that uses a small amount of radioactive material (such as PiB) to produce detailed images of structures and functions within the body, particularly useful for visualizing brain activity and abnormalities.
  • Cerebrospinal Fluid (CSF): A clear, colorless fluid that surrounds the brain and spinal cord. Analyzing CSF can provide important information about the health of the central nervous system and the presence of certain diseases.
  • Cognitive Impairment: A decline in mental abilities such as memory, thinking, and reasoning. In Alzheimer's disease, cognitive impairment progressively worsens over time.
  • Clinical Dementia Rating (CDR): A numeric scale used to quantify the severity of symptoms of dementia. It assesses a person's cognitive and functional performance in six areas: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care.

References

  1. http://clinicaltrials.eu/trial/study-on-lecanemab-and-drug-combination-for-patients-with-early-onset-alzheimers-disease-due-to-genetic-mutation/